{"nctId":"NCT03182725","briefTitle":"Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome","startDateStruct":{"date":"2018-02-06","type":"ACTUAL"},"conditions":["Postural Orthostatic Tachycardia Syndrome"],"count":37,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ivabradine","type":"EXPERIMENTAL","interventionNames":["Drug: Ivabradine"]}],"interventions":[{"name":"Ivabradine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects aged 18-65.\n* Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE\\> 600pg/ml))\n* Subjects with no structural heart disease\n* Subject with no arrhythmias\n* Subjects with norepinephrine levels greater than 600 pg/ml\n* Subjects with normal CBC, Metabolic, and thyroid levels\n\nExclusion Criteria:\n\n* Thyroid or adrenal disorders\n* Drugs that interfere with Ivabradine (example: Cytochrome P450 drugs)\n* Presentation of peripheral edema and discolored toes with peripheral autonomic neuropathy. Symptoms include: legs (reduced hair growth, cramps), toes (blue color), legs/feet (wounds, ulcers that do not heal), and muscles (numbness, heaviness)\n* Subjects who have had a history of systemic illnesses (acute or chronic infectious); autoimmune/ inflammatory disease, cancer, COPD, anemia, diabetes, or psychiatric illness\n* Subjects with resting heart rate\\< 60beats/min, atrial fibrillation, advanced AV blocks, sinus disease, and acute decompensated heart failure and severe hepatic impairment.\n* Smokers or alcohol abuse\n* Pregnant or breastfeeding mothers\n* Woman of childbearing potential who are unwilling to use highly effective contraception during treatment and for an additional one month after discontinuing the study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Heart Rate","description":"Orthostatic heart rate monitoring will be used to gauge heart rate changes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":"10.4"},{"groupId":"OG001","value":"13.1","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life Via SF-36 Survey","description":"Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) The SF-36 has 36 questions and is an indicator of overall health status and is well-validated. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. The total score on the SF-36 ranges from 0 - 100 Lower scores = more disability, higher scores = less disability\n\nSections:\n\nVitality Physical functioning Bodily pain General health perceptions Physical role functioning Emotional role functioning Social role functioning Mental health","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":"22.4"},{"groupId":"OG001","value":"53.4","spread":"27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":[]}}}